A Phase I, Non-randomized, Open-label, Repeat Oral Administration Study of ASP3026 in Patients With Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 18 Jul 2014
At a glance
- Drugs ASP 3026 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Astellas Pharma
- 10 Jun 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 10 Dec 2012 Planned number of patients changed from 54 to 69 as reported by ClinicalTrials.gov.
- 29 Jul 2011 New trial record